Summary
“Compliance alone does not drive quality”
In this Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Mike Cook about the the Voluntary Improvement Program (VIP), and how it can help MedTech leaders go beyond inspection readiness toward true quality maturity.
Mike explains how VIP grew out of FDA’s Case for Quality initiative, why the program uses a maturity-appraisal model rather than a traditional audit model, and how organizations can use it to surface operational weaknesses, strengthen quality culture, and translate quality improvement into business language.
The conversation also explores why many companies struggle to make the business case for proactive QMS improvement, how VIP may help organizations prepare for the expectations of QMSR, and why quality leaders need to connect risk reduction, operational excellence, and sustainable business performance.
Listen to the full 30-minute podcast or jump to a section of interest listed below.
Chapters
00:00 – Introduction01:40 – From Case for Quality to VIP03:45 – What makes VIP different from an audit07:40 – How appraisals reveal QMS maturity11:00 – Translating quality into business language13:00 – Why leaders hesitate to invest in improvement16:05 – Cost, ROI, and regulatory benefits of VIP18:10 – The challenge of status quo21:15 – How VIP may support QMSR readiness24:30 – Key Takeaways
If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.
Suggested links:
LTR: QMSR and the Assurance Mindset: A Leadership Imperative
LTR: How Quality can Help Overcome MedTech R&D Challenges.
LTR: LTR Risk Coach - AI-Powered Decision Support Tool.
Key Takeaways
* Compliance is not the same as quality. VIP grew from the recognition that both compliant and non-compliant companies can still face similar quality and safety problems.
* VIP is not a traditional audit. It uses a third-party appraisal model to assess maturity, capability, and how work is actually performed across the organization.
* Quality improvement needs executive language. Mike emphasized that appraisal results can help translate quality into ROI, risk reduction, cost avoidance, and strategic decision-making input.
* The biggest barrier may be status quo. Many organizations know improvement is needed but struggle to pause reactive work long enough to invest in a different operating model.
* QMSR raises the stakes for maturity. As FDA focuses more on risk-based decisions and QMS effectiveness, maturity models may help companies strengthen internal capability before gaps become visible through inspection.
Keywords
FDA Case for Quality, VIP Program, Voluntary Improvement Program, QMSR, quality maturity, QMS improvement, operational excellence, medical device quality, FDA inspections, risk management, quality culture, continuous improvement, MDIC, CMMI, MedTech leadership, quality systems
About Mike Cook
Mike Cookis a a Strategic Account Executive at MDDAP, LLC, where his work focuses on the Voluntary Improvement Program and helping medical device manufacturers strengthen quality culture, operational excellence, execution consistency, and continuous improvement beyond traditional compliance and audits.
Before joining MDDAP, Mike spent more than six years at Greenlight Guru, a quality management software platform designed specifically for medical device companies. His background includes quality management systems, clinical and SaaS account leadership, diagnostic imaging, healthcare systems, and organizational leadership.
Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn.
Disclaimer
Information and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations.
Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards.
